Jakafi (ruxolitinib tablets) — Cigna
Myeloid or Lymphoid Neoplasms with Eosinophilia and JAK2 rearrangement
Initial criteria
- Patient age ≥ 18 years
- Patient has eosinophilia
- The tumor has a Janus Associated Kinase 2 (JAK2) rearrangement
Approval duration
1 year